Results for tag: "KRAS Inhibitors"

The KRAS inhibitors market is a segment within the broader oncology drugs sector that is focused on the development and commercialization of therapies targeting the KRAS gene mutation. KRAS (Kirsten rat sarcoma viral oncogene homolog) is one of the most common mutations found in human cancers, particularly in pancreatic, colorectal, and lung cancers. The mutation leads to an abnormal form of the KRAS protein, which contributes to the growth and survival of cancer cells. The development of KRAS inhibitors has been challenging due to the difficulty in targeting the protein directly. However, advances in drug design and a deeper understanding of the mutation's structure have led to the discovery of potential small-molecule inhibitors that can bind to and inhibit the mutated KRAS protein, thereby slowing down or stopping the growth of cancer. Several biopharmaceutical companies are active in the KRAS inhibitors market, conducting research and development to bring these targeted therapies to patients. Among these, Amgen stands out as one of the pioneers with its drug sotorasib (Lumakras™) having received approval for treating non-small cell lung cancer (NSCLC) with a specific KRAS mutation. Other notable companies in this market include Mirati Therapeutics, which is developing adagrasib (MRTX849), and Boehringer Ingelheim, which is working on BI 1701963, a SOS1::KRAS inhibitor. Additionally, Revolution Medicines and Wellspring Biosciences are Show Less Read more